Clinical trials / NCT06056297
NCT06056297Phase 3Recruiting

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

Study sponsor: X4 Pharmaceuticals

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov recordCSV export · Pro
Primary completion2027-09Estimated
Enrollment · participants176Estimated
Source updated2026-08-06Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Annualized Infection Rate Based on Infections Adjudicated by Blinded Infection Adjudication Committee (BIAC) During the Treatment Period Measure: Number of Participants Meeting the Definition of a Positive Absolute Neutrophil Count (ANC) Response

+ After

Measure: Co-primary Endpoint: Annualized Infection Rate Based on Infections Adjudicated by Blinded Infection Adjudication Committee (BIAC) During the Treatment Period Measure: Co-primary Endpoint: Number of Participants Meeting the Definition of a Positive Absolute Neutrophil Count (ANC) Response

Planned enrollment increased by 26 participants

− Before

150 participants (planned)

+ After

176 participants (planned)

Primary completion date changed

− Before

Jul 2026

+ After

Sep 2027

Check registry source